Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    November 2017
  1. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Nov 13. doi: 10.1007/s00535-017-1409.
    PubMed     Text format     Abstract available


  2. MAEKAWA S, Sato M, Kuratomi N, Inoue T, et al
    Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1405.
    PubMed     Text format     Abstract available


    October 2017
  3. KUMADA H, Watanabe T, Suzuki F, Ikeda K, et al
    Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    J Gastroenterol. 2017 Oct 20. doi: 10.1007/s00535-017-1396.
    PubMed     Text format     Abstract available


  4. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Text format     Abstract available


    September 2017
  5. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available


    August 2017
  6. KAWAKAMI Y, Ochi H, Hayes CN, Imamura M, et al
    Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
    J Gastroenterol. 2017 Aug 16. doi: 10.1007/s00535-017-1380.
    PubMed     Text format     Abstract available


    May 2017
  7. MIZUOCHI T, Takano T, Yanagi T, Ushijima K, et al
    Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.
    J Gastroenterol. 2017 May 31. doi: 10.1007/s00535-017-1351.
    PubMed     Text format     Abstract available


  8. SUDA G, Furusyo N, Toyoda H, Kawakami Y, et al
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    J Gastroenterol. 2017 May 30. doi: 10.1007/s00535-017-1353.
    PubMed     Text format     Abstract available


    January 2017
  9. UEDA Y, Ikegami T, Akamatsu N, Soyama A, et al
    Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    J Gastroenterol. 2017 Jan 30. doi: 10.1007/s00535-017-1310.
    PubMed     Text format     Abstract available


    December 2016
  10. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Text format     Abstract available


  11. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  12. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  13. MORIO K, Imamura M, Kawakami Y, Nakahara T, et al
    ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  14. TAKEDA H, Takai A, Inuzuka T, Marusawa H, et al
    Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  15. MORIO R, Imamura M, Kawakami Y, Morio K, et al
    Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  16. CHAYAMA K, Hayes CN
    Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
    J Gastroenterol. 2016.
    PubMed     Text format    


  17. TOYOTA J, Karino Y, Suzuki F, Ikeda F, et al
    Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  18. IIO E, Shimada N, Abe H, Atsukawa M, et al
    Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  19. TOYODA H, Kumada T, Tada T, Takaguchi K, et al
    Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    J Gastroenterol. 2016.
    PubMed     Text format    


    February 2016
  20. YOSHIO S, Kanto T
    Host-virus interactions in hepatitis B and hepatitis C infection.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  21. TOYODA H, Kumada T, Tada T, Takaguchi K, et al
    Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  22. SUDA G, Kudo M, Nagasaka A, Furuya K, et al
    Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  23. HIRAMINE S, Sugiyama M, Furusyo N, Uto H, et al
    Erratum to: A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus.
    J Gastroenterol. 2015.
    PubMed     Text format    


    November 2015
  24. KAWAI-KITAHATA F, Asahina Y, Tanaka S, Kakinuma S, et al
    Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  25. HAYASHI N, Nakamuta M, Takehara T, Kumada H, et al
    Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  26. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  27. UCHIDA Y, Kouyama JI, Naiki K, Sugawara K, et al
    Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  28. TAHATA Y, Hiramatsu N, Oze T, Morishita N, et al
    The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  29. KAI Y, Hikita H, Tatsumi T, Nakabori T, et al
    Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    March 2015
  30. FUJIYOSHI M, Kuno A, Gotoh M, Fukai M, et al
    Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  31. GOTO K, Kato N
    MICA SNPs and the NKG2D system in virus-induced HCC.
    J Gastroenterol. 2015;50:261-72.
    PubMed     Text format     Abstract available


    January 2015
  32. TOSHIMA T, Shirabe K, Ikegami T, Yoshizumi T, et al
    A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.
    J Gastroenterol. 2015;50:76-84.
    PubMed     Text format     Abstract available


    October 2013
  33. KUDO A , Tanaka S, Ban D, Matsumura S, et al
    Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis.
    J Gastroenterol. 2013.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: